| Literature DB >> 31892939 |
Chun-Li Piao1, Jin-Li Luo1, Cheng Tang1, Li Wang1, Feng-Mei Lian2, Xiao-Lin Tong2.
Abstract
INTRODUCTION: Radix Salviae (Dan-shen in pinyin), a classic Chinese herb, has been extensively used to treat diabetic retinopathy in clinical practice in China for many years. However, the pharmacological mechanisms of Radix Salviae remain vague. The aim of this study was to decrypt the underlying mechanisms of Radix Salviae in the treatment of diabetic retinopathy using a systems pharmacology approach.Entities:
Keywords: Diabetic retinopathy; Network pharmacology; Radix Salviae
Year: 2019 PMID: 31892939 PMCID: PMC6936117 DOI: 10.1186/s13020-019-0280-7
Source DB: PubMed Journal: Chin Med ISSN: 1749-8546 Impact factor: 5.455
Fig. 1The flowchart of the network pharmacology-based strategy for deciphering the mechanisms of Radix Salviae on DR
The list of 65 compounds of Radix Salviae and their OB and DL
| ID | Compound | OB | DL |
|---|---|---|---|
| MOL001601 | 1,2,5,6-Tetrahydrotanshinone | 38.75 | 0.36 |
| MOL001659 | Poriferasterol | 43.83 | 0.76 |
| MOL001771 | Poriferast-5-en-3beta-ol | 36.91 | 0.75 |
| MOL001942 | Isoimperatorin | 45.46 | 0.23 |
| MOL002222 | Sugiol | 36.11 | 0.28 |
| MOL002651 | Dehydrotanshinone II A | 43.76 | 0.4 |
| MOL002776 | Baicalin | 40.12 | 0.75 |
| MOL000569 | Digallate | 61.85 | 0.26 |
| MOL000006 | Luteolin | 36.16 | 0.25 |
| MOL006824 | α-Amyrin | 39.51 | 0.76 |
| MOL007036 | 5,6-Dihydroxy-7-isopropyl-1,1-dimethyl-2,3-dihydrophenanthren-4-one | 33.77 | 0.29 |
| MOL007041 | 2-Isopropyl-8-methylphenanthrene-3,4-dione | 40.86 | 0.23 |
| MOL007045 | 3α-HydroxytanshinoIIa | 44.93 | 0.44 |
| MOL007048 | (E)-3-[2-(3,4-dihydroxyphenyl)-7-hydroxy-benzofuran-4-yl]acrylic acid | 48.24 | 0.31 |
| MOL007049 | 4-Methylenemiltirone | 34.35 | 0.23 |
| MOL007050 | 2-(4-Hydroxy-3-methoxyphenyl)-5-(3-hydroxypropyl)-7-methoxy-3-benzofurancarboxaldehyde | 62.78 | 0.4 |
| MOL007051 | 6- | 46.69 | 0.71 |
| MOL007058 | Formyltanshinone | 73.44 | 0.42 |
| MOL007059 | 3-Beta-hydroxymethyllenetanshiquinone | 32.16 | 0.41 |
| MOL007061 | Methylenetanshinquinone | 37.07 | 0.36 |
| MOL007063 | Przewalskin a | 37.11 | 0.65 |
| MOL007064 | Przewalskin b | 110.32 | 0.44 |
| MOL007068 | Przewaquinone B | 62.24 | 0.41 |
| MOL007069 | Przewaquinone c | 55.74 | 0.4 |
| MOL007070 | (6S,7R)-6,7-dihydroxy-1,6-dimethyl-8,9-dihydro-7H-naphtho[8,7-g]benzofuran-10,11-dione | 41.31 | 0.45 |
| MOL007071 | Przewaquinone f | 40.31 | 0.46 |
| MOL007077 | Sclareol | 43.67 | 0.21 |
| MOL007079 | Tanshinaldehyde | 52.47 | 0.45 |
| MOL007081 | Danshenol B | 57.95 | 0.56 |
| MOL007082 | Danshenol A | 56.97 | 0.52 |
| MOL007085 | Salvilenone | 30.38 | 0.38 |
| MOL007088 | Cryptotanshinone | 52.34 | 0.4 |
| MOL007093 | Dan-shexinkum d | 38.88 | 0.55 |
| MOL007094 | Danshenspiroketallactone | 50.43 | 0.31 |
| MOL007098 | Deoxyneocryptotanshinone | 49.4 | 0.29 |
| MOL007100 | Dihydrotanshinlactone | 38.68 | 0.32 |
| MOL007101 | Dihydrotanshinone I | 45.04 | 0.36 |
| MOL007105 | Epidanshenspiroketallactone | 68.27 | 0.31 |
| MOL007107 | C09092 | 36.07 | 0.25 |
| MOL007108 | Isocryptotanshi-none | 54.98 | 0.39 |
| MOL007111 | Isotanshinone II | 49.92 | 0.4 |
| MOL007115 | Manool | 45.04 | 0.2 |
| MOL007118 | Microstegiol | 39.61 | 0.28 |
| MOL007119 | Miltionone I | 49.68 | 0.32 |
| MOL007120 | Miltionone II | 71.03 | 0.44 |
| MOL007121 | Miltipolone | 36.56 | 0.37 |
| MOL007122 | Miltirone | 38.76 | 0.25 |
| MOL007123 | Miltirone II | 44.95 | 0.24 |
| MOL007124 | Neocryptotanshinone ii | 39.46 | 0.23 |
| MOL007125 | Neocryptotanshinone | 52.49 | 0.32 |
| MOL007127 | 1-Methyl-8,9-dihydro-7H-naphtho[5,6-g]benzofuran-6,10,11-trione | 34.72 | 0.37 |
| MOL007130 | Prolithospermic acid | 64.37 | 0.31 |
| MOL007132 | (2R)-3-(3,4-dihydroxyphenyl)-2-[(Z)-3-(3,4-dihydroxyphenyl)acryloyl]oxy-propionic acid | 109.38 | 0.35 |
| MOL007140 | (Z)-3-[2-[(E)-2-(3,4-dihydroxyphenyl)vinyl]-3,4-dihydroxy-phenyl]acrylic acid | 88.54 | 0.26 |
| MOL007141 | Salvianolic acid g | 45.56 | 0.61 |
| MOL007142 | Salvianolic acid j | 43.38 | 0.72 |
| MOL007143 | Salvilenone I | 32.43 | 0.23 |
| MOL007145 | Salviolone | 31.72 | 0.24 |
| MOL007149 | NSC 122421 | 34.49 | 0.28 |
| MOL007150 | (6S)-6-Hydroxy-1-methyl-6-methylol-8,9-dihydro-7H-naphtho[8,7-g]benzofuran-10,11-quinone | 75.39 | 0.46 |
| MOL007151 | Tanshindiol B | 42.67 | 0.45 |
| MOL007152 | Przewaquinone E | 42.85 | 0.45 |
| MOL007154 | Tanshinone iia | 49.89 | 0.4 |
| MOL007155 | (6S)-6-(hydroxymethyl)-1,6-dimethyl-8,9-dihydro-7H-naphtho[8,7-g]benzofuran-10,11-dione | 65.26 | 0.45 |
| MOL007156 | Tanshinone VI | 45.64 | 0.3 |
Fig. 2The C-T network that consists of 24 nodes and 247 targets. Yellow and blue nodes denote the compounds and targets, respectively
Fig. 3The T-D network that consists of 287 nodes and 247 targets. Pink and yellow nodes denote the diseases and targets, respectively
Fig. 4The 18 matching targets of the related targets in Radix Salviae on DR. DR diabetic retinopathy
Fig. 5PPI network of 18 nodes and 40 edges established in the String database
Fig. 6Main 30 GO biological process by major hubs from the DAVID database
Fig. 7The main 10 pathways enriched by major hubs from the DAVID database
Fig. 8Illustration of the crucial biological processes caused by putative targets and known therapeutic targets for DR. MMP2 matrix metallopeptidase 2, hsp60 heat shock protein 60, Cyt3 cytochrome 3, PLG plasminogen, PLM plasmin, tPA tissue plasminogen activator, PAI plasminogen activator inhibitor, RECK reversion-inducing cysteine-rich protein with Kazal motifs, MMP9 matrix metallopeptidase 9, TIMP 1 tissue inhibitor of metalloproteinases 1, TIMP 2 tissue inhibitor of metalloproteinases 2, TIMP 4 tissue inhibitor of metalloproteinases 4, ECM extracellular matrix, IGF-1 insulin-like growth factor-1, IGF-1R insulin-like growth factor-1 receptor, PI3K phosphatidylinositol 3-kinase, AKT serine-threonine kinase, VEGF vascular endothelial growth factor, KDR vascular endothelial growth factor receptor 2, AQP-1 aquaporin-1, COX-2 cyclooxygenase-2, PGH2 prostaglandin H2, PGE2 prostaglandin E2, PGES prostaglandin E2 synthase